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Abstract 
 
Despite recent advances in our ability to detect adaptive evolution involving the cis-regulation of 
gene expression, our knowledge of the molecular mechanisms underlying these adaptations has 
lagged far behind. Across all model organisms the causal mutations have been discovered for 
only a handful of gene expression adaptations, and even for these, mechanistic details (e.g. the 
trans-regulatory factors involved) have not been determined. We previously reported a polygenic 
gene expression adaptation involving down-regulation of the ergosterol biosynthesis pathway in 
the budding yeast Saccharomyces cerevisiae. Here we investigate the molecular mechanism of a 
cis-acting mutation affecting a member of this pathway, ERG28. We show that the causal 
mutation is a two-base deletion in the promoter of ERG28 that strongly reduces the binding of 
two transcription factors, Sok2 and Mot3, thus abolishing their regulation of ERG28. This down-
regulation increases resistance to a widely used antifungal drug targeting ergosterol, similar to 
mutations disrupting this pathway in clinical yeast isolates. The identification of the causal 
genetic variant revealed that the selection likely occurred after the deletion was already present at 
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high frequency in the population, rather than when it was a new mutation. These results provide 
a detailed view of the molecular mechanism of a cis-regulatory adaptation, and underscore the 
importance of this view to our understanding of evolution at the molecular level. 
 
 
 
 
 
 
 
 
 
 
Author Summary 
 
Evolutionary adaptation is the process that has given rise to the ubiquitous, yet 
remarkable, fit between all living organisms and their environments. The molecular mechanisms 
of these adaptations have been a subject of great interest, but we still know very little about their 
mechanisms, particularly in the case of regulatory adaptations. In this work, we investigate the 
molecular mechanism of a regulatory adaptation that we previously identified in ERG28, a 
component of the ergosterol biosynthesis pathway in budding yeast. Ergosterol is an abundant 
lipid component of the fungal plasma membrane, and is of major biomedical importance, being 
targeted by numerous antifungal drugs. We identified the causal mutation underlying the ERG28 
adaptation, a two-base deletion in its promoter which leads to lower abundance of its mRNA. 
This deletion acts via disrupting the binding of at least two transcription factors, Mot3 and Sok2, 
to the promoter. The deletion increases resistance to a widely used antifungal drug, 
Amphotericin B, which targets ergosterol. This effect is reminiscent of misregulation of the 
ergosterol pathway observed in clinical yeast isolates that have evolved resistance to 
Amphotericin B. Our results may therefore have medical implications, while also advancing our 
basic understanding of evolutionary mechanisms.  
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Introduction 
 
 Evolutionary adaptation is the process that has given rise to the ubiquitous, yet 
remarkable, fit between all living organisms and their environments [1]. The origins of these 
adaptations at the molecular level have been a subject of great interest, with active debate 
surrounding the relative roles of two major classes of molecular mechanism: changes in protein 
sequences vs. changes in the expression levels/patterns of those proteins [2-5]. Until recently, the 
evidence cited in favor of both mechanisms was either anecdotal (involving studies of single 
genes) or theoretical in nature [2-4]. However, the advent of methods for characterizing gene 
expression adaptation genome-wide [6-9] (as well as methods for measuring cis-regulatory 
changes that may or may not be adaptive [10-11]) has paved the way for this question to be 
addressed in an unbiased, systematic fashion [5]. 
 Although the distinction between protein sequence vs. gene expression regulation is 
important, it is only one of many levels at which molecular mechanisms can be distinguished. 
For example among cis-regulatory adaptations, mutations might act via alterations in 
transcription factor (TF) binding, nucleosome positioning, mRNA processing, binding of RNA-
binding proteins, etc. As the field matures, it is likely that the distinctions between these more 
detailed mechanistic levels will be of increasingly greater interest, since only by investigating 
these mechanisms will we fully understand the nature of adaptation at the molecular level. 
 In order to investigate the molecular mechanism of an adaptation, it is generally 
necessary to first identify the causal mutation(s) (though see [12]). This prerequisite has been a 
significant bottleneck in studies of cis-regulatory adaptation. Because we cannot computationally 
predict the effects of most non-coding mutations, and such mutations can act at long distances 
from their target genes in many species (resulting in a large search space), only a handful of 
causal mutations underlying cis-regulatory adaptations have been reported. For example, large 
deletions of an enhancer driving the pelvic expression of the Pitx1 gene in sticklebacks have 
been found to result in adaptive pelvic reduction in freshwater populations [13]. In another case, 
five non-coding mutations at the ebony locus contributed to dark abdominal pigmentation found 
in high-altitude populations of Drosophila melanogaster [14] (although other examples exist 
where causal cis-regulatory mutations have been identified in various model organisms [15-17], 
these have not been shown to be adaptive). However even for these intensively studied cis-
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regulatory adaptations, the molecular mechanisms by which the causal mutations act—e.g. which 
TFs and/or epigenetic states are affected by the mutations—remain unknown.   
 We previously reported a genome-wide scan for gene expression adaptation between two 
strains of the budding yeast Saccharomyces cerevisiae: a laboratory strain (BY4716, hereafter 
“BY”) and a vineyard strain (RM11-1a, hereafter “RM”) [8]. We found that over 200 genes had 
likely been subject to recent positive selection in these strains via the action of reinforcing cis 
and trans-acting regulatory adaptations. Among these genes, there was a strong enrichment of 
down-regulating mutations in one metabolic pathway: ergosterol biosynthesis. Ergosterol is an 
abundant lipid component of the fungal plasma membrane, and is of major biomedical 
importance, being targeted by numerous antifungal drugs [18]. Indeed, a common mechanism of 
resistance to ergosterol-targeting drugs (such as amphotericin B) is reducing ergosterol levels via 
disruption of this pathway [18-21]. We previously found that six genes within the pathway 
(underlined and red in Figure 1A) showed the strongest signs of selection, based on patterns of 
reinforcing cis/trans-regulatory mutations, as well as a population-genetic signature of selective 
sweeps in the genomes of multiple strains [8]. This represents the first known example of a 
polygenic gene expression adaptation, from any species. Here, we sought to gain a deeper 
understanding of this adaptation.  
 
Results 
 
Further characterization of the ergosterol pathway adaptation 
 
 Because our initial identification of the polygenic gene expression adaptation within the 
ergosterol (ERG) biosynthesis pathway was based on expression data from genome-wide 
microarrays [22], we first sought to more precisely measure the cis-regulatory divergence at 
these loci. This divergence can be measured for any gene as the ratio of mRNA abundances of 
the two alleles present in a hybrid diploid: in the absence of cis-acting differences, the mRNA 
from the two alleles will be present in equal amounts (as they are in the genomic DNA), whereas 
they will be unequal in the presence of cis-regulatory divergence. To measure this ratio we 
employed pyrosequencing, a method that accurately quantifies allelic ratios at individual 
heterozygous sites [23].  
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Of the six genes we previously implicated, five were amenable to this approach (the 
sixth, ERG26, lacked any BY/RM sequence differences in its mRNA, so the alleles could not be 
distinguished). All five showed reproducible allelic imbalance in the expected direction (lower 
expression from the BY allele), with magnitudes ranging from 1.13-fold to 1.94-fold (Figure 
1B). This result confirms that the “local eQTL” (genetic markers showing a statistical association 
with a nearby gene’s expression level) previously mapped for these genes [22] likely represent 
cis-acting genetic variants. 
To investigate if the polygenic adaptation extends beyond the six genes we originally 
identified, we also performed pyrosequencing on three additional ERG genes adjacent in the 
pathway to those already implicated: ERG25, ERG27, and ERG2 (allelic bias of ERG1, the other 
adjacent pathway member, could not be measured because it has no sequence differences 
between BY and RM). We found reproducible allelic bias in favor of RM for both ERG25 and 
ERG27, but not for ERG2 (Figure 1B). This suggests that the adaptive down-regulation extends 
to a total of at least eight genes, forming a contiguous block within the ERG pathway (Figure 
1A, in red) that has been specifically targeted by natural selection. 
Interestingly, in addition to the clear clustering of the down-regulated genes within the 
pathway, the genes with the strongest cis-regulatory differences correspond precisely to the core 
proteins in a stable complex organized by Erg28. Erg28 is the only known member of the ERG 
pathway lacking enzymatic activity; it is an endoplasmic reticulum transmembrane protein, 
highly conserved across eukaryotes (including humans), that acts as a scaffold promoting co-
localization of ERG enzymes [24-26]. Erg28 physically interacts most strongly with Erg27 (and 
is thus shown next to Erg27 in Figure 1), but has also been found to interact strongly with itself 
and three other proteins: Erg25, Erg6, and Erg11; its other interactions are significantly weaker 
[24]. These five interacting proteins are not only all components of the polygenic adaptation 
(Figure 1), but are specifically those components with the strongest cis-acting down-regulation: 
all five have at least 1.25-fold differences between RM and BY alleles, while no other genes 
quite reach this threshold (Figure 1B). This pattern suggests that the precise magnitude of down-
regulation may be influenced both by pathway position and by membership in the protein 
complex organized by Erg28.  
 
Pinpointing a causal adaptive mutation 
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 We decided to focus on ERG28 for further investigation. Not only is Erg28 the central 
member of the protein complex apparently targeted by natural selection, but sequence divergence 
in its promoter region was also minimal: there are only two sequence differences between BY 
and RM in the 590 bp upstream of the ERG28 transcription start site (TSS). These are one two-
bp deletion (located in an 11 bp poly-A tract 112 bp upstream of the TSS, termed the AA112∆ 
allele), and one T/C SNP (229 bp upstream of the TSS, the T229C allele) (Figure 2A). Because 
promoters in S. cerevisiae are compact (generally < 400 bp [27]), we decided to focus on these 
two candidate variants. 
To definitively identify the mutation(s) underlying a cis-regulatory adaptation, the 
mutations must be individually tested for their effects on expression of the associated gene. 
Therefore we constructed allelic replacement strains in which individual BY variants were 
introduced into the RM genome. Using a method of in vivo site-directed mutagenesis known as 
delitto perfetto [28], we engineered strains that differed only by the desired mutation. We refer to 
the two resulting strains as RM AA112∆ and RM T229C (Figure 2b).  
If a mutation can fully account for the 1.30-fold cis-acting difference between the 
RM/BY alleles of ERG28 (Figure 1B), and no additional mutations have any effect, then this 
mutation can be deemed causal. To test if this was the case for either of our candidate mutations, 
we measured the expression level of ERG28 in each strain, as well as in wild-type RM, by 
quantitative PCR (qPCR). While we found no effect of the T229C mutation (1.05-fold 
difference), we observed that the AA112∆ mutation led to a 1.26-fold decrease in mRNA level 
(Figure 2c), indistinguishable from the 1.30-fold change expected for the causal mutation(s).  
To further test if the AA112∆ mutation could fully account for the RM/BY difference, we 
mated the RM AA112∆ strain with BY, and measured the allelic ratio of ERG28 mRNA in the 
resulting diploid strain. The causal mutation would be expected to reduce the 1.30-fold allelic 
difference to ~1, while any non-causal mutation would have the same the 1.30-fold allelic 
imbalance found in the BY/RM hybrid. Consistent with the qPCR results, the RM AA112∆/BY 
hybrid strain showed a 1.03-fold difference between alleles, while the RM T229C/BY hybrid 
showed a 1.27-fold difference (Figure 2d). Together, these results suggested that the AA112∆ 
mutation likely accounted for all, or nearly all, of the cis-acting divergence at ERG28 between 
RM and BY. 
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The molecular mechanism of the ERG28 cis-regulatory adaptation 
 
 We considered two potential mechanisms for how the AA112∆ mutation may be down-
regulating transcription: nucleosome positioning and TF binding. Both processes are known to 
play important roles in determining rates of transcription initiation, and could potentially be 
affected by a 2-bp deletion. 
Nucleosome positioning was an especially plausible mechanism because the 11-bp poly-
A sequence in which the 2-bp deletion occurred is a strong nucleosome-disfavoring sequence 
[29]. Therefore we took advantage of published data on genome-wide nucleosome positions 
from BY and RM [30] to determine whether the nucleosome overlapping the deletion was 
affected. There was no significant difference between BY and RM in the nucleosomal occupancy 
or positioning at this location (nor was it differentially acetylated on histone H3 lysine 14 [30]), 
suggesting that nucleosome occupancy was not greatly affected by this deletion. 
We therefore turned to TF binding as a second possible mechanism. Utilizing a published 
map of putative TF binding sites [31] we identified two highly conserved (across Saccharomyces 
sensu stricto) binding sites for the TFs Mot3 and Sok2, flanking the deletion (Figure 3a). Mot3 is 
a well-known repressor of ERG pathway genes, exerting its greatest effect in hypoxic or hyper-
osmotic conditions [32-33], whereas Sok2 has not been previously linked to the ERG pathway to 
our knowledge. Neither binding site motif is directly affected by the 2-bp deletion; rather the 
only effect is on their spacing, reducing the distance between motif centers from 16 bp to 14. 
To test if the AA112∆ deletion may affect the regulation of ERG28 by either of these two 
TFs, we created knockout strains for each TF in both the wild-type RM and RM AA112∆ 
backgrounds. Several outcomes are possible (Figure 3b). First, if the TF does not regulate 
ERG28, then deleting it should have no effect in either genetic background. Second, if the TF 
does regulate ERG28 but is not affected by the AA112∆ deletion, then the effect of TF deletion 
should be equal in the two backgrounds. Finally, if the AA112∆ deletion is affecting the TF’s 
regulation of ERG28, then the effect of TF deletion will depend on the background—for 
example, having an effect on ERG28 expression in wild-type RM but not in RM AA112∆. 
Consistent with Mot3’s known role as a repressor of ERG pathway genes, we found that 
ERG28 was induced 1.85-fold in an RM mot3∆ strain compared with wild-type RM (Figure 3c). 
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Likewise, Sok2 was found to be an activator of ERG28, with 1.21-fold lower expression in RM 
sok2∆ compared to wild-type RM. However neither TF had any measurable effect on ERG28 
expression when deleted from the RM AA112∆ strain (Figure 3c). This suggests that although 
both TFs regulate ERG28 in RM, this regulation was abolished by the 2-bp deletion.  
The effect of AA112∆ on regulation of ERG28 by Mot3 and Sok2 suggested that their 
binding to the promoter may be affected by the deletion. To investigate this, we performed 
chromatin immunoprecipitation (ChIP). Specifically, we HA-tagged both TFs in both wild-type 
RM and RM AA112∆ backgrounds, and quantified their binding to specific regions by 
quantitative PCR (qPCR). We found that for both factors, binding at the ERG28 promoter was 
reduced in RM AA112∆, compared to wild-type RM: Sok2 showed ~19-fold lower binding, 
while Mot3 had ~31-fold lower binding (Figure 3d). This suggests that the loss of ERG28 
regulation by these TFs in the AA112∆ background (Figure 3c) is likely due to their severely 
reduced binding. 
 
Fitness effects of the ERG28 cis-regulatory adaptation 
 
In order to investigate the phenotypic effects of the AA112∆ allele, we measured the 
growth rates of our engineered strains and RM in several environments (see Materials and 
Methods). While we did not observe any fitness advantage of the RM AA112∆ strain in most 
conditions (e.g. rich synthetic defined [SD] media; paired t-test p = 0.46 for RM AA112∆ vs. 
RM and p = 0.83 for RM T229C vs. RM; Figure 4a), we did find a growth advantage of this 
strain in the presence of the antifungal drug amphotericin B (Figure 4b). Specifically, RM 
AA112∆ had a 1.3% higher growth rate than RM when grown in the presence of the drug (p = 
0.014), whereas RM T229C had no measurable difference from RM (p = 0.86). This suggests 
that the fitness benefit conferred by the AA112∆ allele is condition-specific. 
 
Insights into the selection on ERG28 cis-regulation 
 
Our identification of the AA112∆ allele as causal allows us to examine the distribution of 
this adaptive mutation across other yeast strains, in order to study its history. In particular, we 
wished to address the question of whether the selection occurred when the deletion was a new 
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mutation that just recently arose (e.g. in the laboratory), or whether it was present as “standing 
variation” in S. cerevisiae for some time before the selection occurred. Population geneticists 
have theorized about the consequences of selection acting on pre-existing variation, as opposed 
to waiting for rare advantageous mutations to occur, but few clear examples exist [34-36]. 
To distinguish between these alternatives, we first examined the distribution of the 
AA112∆ allele across a set of 36 sequenced strains of S. cerevisiae [37]. The deletion is present 
in 12/36 sequenced strains (in addition to BY; Figure S1). These 12 strains are diverse in terms 
of both geography (from the Americas, Asia, Africa, and Europe) and lifestyle (lab strains, wild 
strains, sake strains, palm wine strains, and other fermentation strains). Furthermore they are 
genetically diverse, as evidenced by their lack of clustering within the S. cerevisiae phylogeny 
(Figure S1). This broad distribution across the species suggests that the AA112∆ allele is present 
at appreciable frequency in many populations of S. cerevisiae. 
To further investigate this, we sequenced the ERG28 promoter in EM93, the wild strain 
that accounts for ~88% of the BY genome [38-39]. Since EM93 is a diploid, we sequenced the 
promoter in the four spores from a single EM93 tetrad, in order to capture both alleles with no 
ambiguity. We found that the AA112∆ mutation was heterozygous within EM93, supporting our 
inference that it is commonly found in the wild. Together, these results suggest that the selection 
on ERG28 in the BY lineage [8] was likely acting on standing variation, as opposed to a new 
mutation. Because EM93 is heterozygous, we can infer the selective sweep most likely occurred 
in the descendants of EM93, after its introduction to the laboratory. 
To attempt a similar analysis for the seven other ERG genes involved in this adaptation 
(Figure 1A), we sequenced their promoters in the same four EM93 spores. Because we do not 
know the causal variants, we performed this analysis at the level of promoter haplotypes (sets of 
co-occurring alleles). We found that for all seven genes, the complete BY promoter haplotype 
was either homozygous (for two genes, ERG25 and ERG26) or heterozygous (for five genes) in 
EM93, indicating that their cis-acting down-regulations were likely not due to new mutations 
occurring in the lab. Each of these BY haplotypes was also observed in between zero and six 
additional sequenced strains, indicating that some of the haplotypes are segregating at an 
appreciable frequency in S. cerevisiae. However the absence of a complete BY haplotype does 
not imply the absence of the causal BY variant, since most ERG promoter variants are not in 
perfect linkage disequilibrium with their neighboring variants. For example, although the 
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AA112∆ variant was found in 12 strains (Figure S1), only five of these also had the T229C 
variant (and thus the complete BY promoter haplotype). This highlights the importance of 
identifying causal variants in order to study the evolutionary histories of specific adaptations. 
 
Discussion 
 
We have identified the causal mutation underlying a cis-regulatory adaptation that affects 
the ergosterol biosynthesis pathway in yeast, and characterized its molecular mechanism of 
action. The mutation, a 2 bp promoter deletion, reduces the expression of ERG28 by ~1.3-fold. 
This effect is mediated by two TFs, Mot3 and Sok2, which bind immediately adjacent to the 
deletion; these TFs bind and regulate the wild-type RM ERG28 promoter, but not the ERG28 
AA112∆ promoter. 
Although it may seem surprising that a 2 bp deletion outside of TF binding sites can have 
such a strong effect on TF binding, it is consistent with previous work. First, most between-strain 
variation in the binding of the Ste12 TF in yeast cannot be linked to variation in any known TF 
motif, even when only considering those binding sites where occupancy was associated with 
nearby genetic markers [40]. Second, it was recently shown that changes in the positions of TF 
binding sites as small as 1-2 bp can result in substantial (>1.5-fold) effects on transcription [41]. 
Finally, minor changes in the copy number of very short tandem repeats in yeast promoters can 
also impact transcription [42].  
It is also at first counterintuitive that decreased binding of a repressor (Mot3) could 
contribute to the down-regulation of ERG28 by AA112∆, in particular since the repressive 
effects of Mot3 appear to be stronger than the activation by Sok2 (Figure 3C). We hypothesize 
that the AA112∆ mutation may have altered the TF binding landscape upstream of ERG28, not 
only for Mot3 and Sok2, but possibly for other TFs as well. The deletion’s effect on transcription 
would then be determined by this altered landscape.  
In addition to the focus on ERG28, our results also further characterize the polygenic 
ERG pathway adaptation as a whole. We found that two genes not implicated in our previous 
analysis of microarray data [8], ERG25 and ERG27, also show reduced expression from the BY 
allele (compared to RM). Moreover, our precise measurements of the cis-acting effect size for 
each ERG gene led us to an intriguing discovery: the five proteins that form the core of a 
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complex at the ER membrane are also the five with the strongest cis-regulatory change. This 
pattern suggests an exquisite specificity of selection, in which the precise level of down-
regulation is determined not only by position within the pathway, but also by membership in a 
specific protein complex. 
While a handful of causal mutations underlying cis-regulatory adaptations in other model 
organisms have been previously reported [10-11], their molecular mechanisms are unknown. 
Compared to these, our knowledge of the ERG28 AA112∆ mutation is now relatively detailed, 
though still incomplete; for example, how the deletion disrupts binding has not been established. 
A plausible explanation is that Sok2 and Mot3 may bind cooperatively to the ERG28 promoter in 
wildtype RM; if this cooperativity is disrupted by the 2-bp deletion (which moves the binding 
sites closer together and changes their relative angles by ~70º), then neither factor would bind 
well to the AA112∆ promoter. 
At the phenotypic level, we found that AA112∆ confers a condition-specific growth 
advantage in the presence of the antifungal drug amphotericin B. Because the AA112∆ mutation 
may also lead to a fitness advantage in other environments that were not tested, we cannot 
conclude whether amphotericin B is related to the specific selection pressure that gave rise to the 
ERG pathway adaptation in BY. However our results are quite consistent with previous 
observations that the down-regulation or deletion of ERG pathway genes confers resistance to 
amphotericin B in diverse clinical yeast isolates [18-21]. Thus our results may shed light on 
potential molecular mechanisms by which antifungal drug resistance can evolve. 
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Materials and Methods 
 
Strain construction 
 We carried out all strain engineering in RM, as opposed to BY, because BY contains a 
very recent loss-of-function transposon insertion in the transcription factor HAP1, which alters 
the regulation of many ERG genes, including ERG28. Because this mutation was so recent (not 
even present in the very closely related lab strain W303 [8]), it must have happened after the 
ERG28 cis-regulatory adaptation, so the functional HAP1 in RM should more accurately reflect 
the original effects of any cis-regulatory mutations.  
In vivo site-directed mutagenesis, known as delitto perfetto, was performed as described 
[27]. Briefly, the pCORE-UH cassette, containing K. lactis URA3 and hyg, was amplified using 
primers containing ~70 bp of homology to the RM ERG28 promoter (Table S1). This PCR 
product was transformed into RM, and correct incorporation into the ERG28 promoter was 
verified by PCR. The site of incorporation was chosen in between the two candidate genetic 
variants, so that the same CORE cassette transformant could be used for engineering both 
mutations. The CORE cassette was then removed by separately transforming two PCR products 
from the BY ERG28 promoter, containing the desired mutation (either AA112∆ or T229C) as 
well as enough flanking DNA sequence (identical between RM and BY) to allow specific 
targeting of the PCR product. Because the efficiency of delitto perfetto is maximized when 
transforming longer DNA molecules, as well as double-stranded DNA [20], transforming long 
PCR products from BY (as opposed to shorter, single-stranded synthetic oligonucleotides) is a 
useful modification. Counter-selection of the resulting transformants on 5-FOA allowed isolation 
of successfully engineered strains that had replaced the CORE cassette with the desired mutation, 
which were then sequence-verified. 
 The complete coding regions of MOT3 and SOK2 were replaced with the hphMX6 
antibiotic resistance gene via PCR-mediated gene disruption [43] in both RM and RM AA112∆. 
Transformants were grown on hygromycin B, and verified by PCR. These two TFs were also 
HA-tagged at their C-termini via transformation of a PCR product including the HA tag, 
hphMX6, and flanking regions with 40 bp of homology to the targeted regions [43]. 
Transformants were grown on hygromycin B, and then verified by PCR and sequencing.  
 Table S2 lists all strains used in this work. 
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Growth conditions 
 With the exception of growth rate experiments (Figure 4), all strains were grown in 
standard YPD media at 30°C, and harvested in log-phase (OD600 ~1) for either RNA extraction 
or chromatin immunoprecipitation. 
  
RNA extraction and cDNA synthesis 
 We extracted total RNA with the Epicentre Biotechnologies RNA Purification kit, which 
includes a DNase treatment to remove contaminating genomic DNA. RNA concentration was 
quantified with a NanoDrop2000 spectrophotometer. For cDNA synthesis, total RNA samples 
were diluted to a concentration of 500ng/µL. RNA was reverse transcribed into cDNA with 
SuperScript III RT (Invitrogen), following manufacturer protocols.  
 
Pyrosequencing 
 Pyrosequencing was performed on a PyroMark Q24 (Qiagen), following manufacturer’s 
protocols. Primers (Table S1) were designed to target individual SNPs in transcribed regions 
using the PyroMark Assay Design Software (Qiagen). Negative controls using no primers, or no 
cDNA template, were performed for each assay. 
 
Quantitative PCR 
 cDNA was diluted 1:100 prior to qPCR. qPCR was performed on an Eco Real-Time PCR 
machine (Illumina) following manufacturer’s protocols. To quantify changes in ERG28 mRNA 
abundance, six control genes previously noted for their stability across conditions [44] were 
measured in each experiment: ACT1, TDH3, ALG9, TAF10, TFC1, and UBC6. All experiments 
were done in at least biological triplicate and technical duplicate. Experiments in Figure 3c were 
done in biological sextuplicate and technical quadruplicate. Data were analyzed using qBase Plus 
software (Biogazelle) [45].  
 
Chromatin immunoprecipitation 
Chromatin immunoprecipitation (ChIP) was performed essentially as described [46]. 
Briefly, wildtype cells and cells expressing either Mot3-HA or Sok2-HA were grown to mid-log 
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phase in 100mL YPD. Cross-linking was performed by treating yeast with 1% formaldehyde for 
15 minutes at 25°C. Chromatin was isolated from whole-cell extracts generated by 
spheroplasting and sheared by sonication. Immunoprecipitation was performed from 5µg 
chromatin using mouse monoclonal anti-HA (Invitrogen, clone 5B1D10) and immune complexes 
were captured with Ultralink Immobilized Protein A/G resin (Pierce). Protein-DNA complexes 
were eluted with 1% SDS/0.1 M NaHCO3. Eluates were incubated at 65°C overnight to reverse 
cross-links and treated with proteinase K (Invitrogen) and RNAse A. DNA was phenol-
chloroform extracted, ethanol-precipitated, and resuspended in water prior to qPCR.  
ChIP DNA was amplified on an Eco Real-Time PCR machine (Illumina) following 
manufacturer’s protocols. We quantified the abundance of the ERG28 promoter region 
containing the Mot3 and Sok2 binding sites, as well as part of the ACT1 coding region as a 
control to quantify the amount of DNA in each reaction. The concentration of ERG28 promoter 
DNA was normalized against this control before comparing across genetic backgrounds (RM vs. 
RM AA112∆) for each TF. 
 
Quantitative growth rate measurements 
To perform quantitative growth rate measurements (Figure 4), we grew strains in 96-well 
plates and measured OD600 at 15-minute intervals using an automated plate reader (Tecan) until 
cultures reached saturation. Data shown in Figure 4 are the mean log2 ratios of the maximum 
log-phase growth rates (estimated by Magellan software, Tecan) for 48 replicate growth curves 
of each strain. Growth conditions were SD media alone or 0.8 ug/ml amphotericin B in SD 
media, both at room temperature (22°C). P-values were calculated using a paired t-test, pairing 
wells in the same row on each plate. Other conditions tested in an initial screening phase were 
hyperosmotic stress (NaCl or menadione) and temperature stress (heat/freezing).  
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Figure Legends 
 
Figure 1. A polygenic gene expression adaptation in the ergosterol biosynthesis (ERG) pathway. 
(A) The final steps of the ERG pathway. Eight genes whose down-regulation contributes to a 
polygenic gene expression adaptation are colored red; the six previously implicated genes [8] are 
underlined. Erg28 is shown next to its strongest interaction partner, Erg27. (B) Allelic bias of 
ERG genes, as measured by pyrosequencing in the RM/BY hybrid. The allelic bias indicates the 
magnitude of cis-regulatory divergence between RM and BY for each gene. Red color indicates 
genes that are part of the polygenic adaptation. Asterisks indicate those that interact strongly 
with Erg28 [24], all of which have stronger allelic bias than those that do not. 
 
Figure 2. Pinpointing the causal mutation affecting ERG28 cis-regulation. (A) Sequence 
divergence between RM and BY in the ERG28 promoter region. No other differences exist for 
590 bp upstream of the gene, or in the 5' UTR. (B) Genotypes at the two variable positions for 
RM, BY, and the two engineered strains. (C) The mRNA levels of ERG28 in each of the two 
engineered strains compared to wildtype RM, assayed by qPCR. The causal mutation is expected 
to result in a ~1.30-fold difference, matching the allelic bias observed in the RM/BY hybrid 
(Figure 1B), whereas any non-causal mutation will not alter the RM expression level (~1-fold 
change). (D) Allelic expression bias in hybrids between each engineered strain and BY, assayed 
by pyrosequencing. Any non-causal mutation will not alter the 1.30-fold RM/BY allelic bias, 
whereas the causal mutation is expected to be expressed at the same level as the BY allele (~1-
fold allelic bias).  
 
Figure 3. Determining the molecular mechanism of the causal mutation. (A) Two predicted 
transcription factor (TF) binding sites flanking the deletion. (B) The expected fold-change in 
ERG28 expression level when deleting TFs under different scenarios. Left: if a TF does not 
regulate ERG28, its deletion should have no effect on ERG28 levels. Center: If a TF regulates 
ERG28 and acts independently of the two-base deletion, then deleting the TF should result in 
some fold-change X, which will be observed in both the wildtype RM and RM AA112∆ 
backgrounds. Right: If a TF regulates the wildtype ERG28 promoter, but the deletion abolishes 
this regulation, then the TF deletion may only affect ERG28 mRNA levels in the wildtype 
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background (A fourth possible scenario, not shown, is where the TF only regulates ERG28 in 
RM AA112∆). (C) qPCR data showing changes in ERG28 mRNA levels upon deleting either 
SOK2 or MOT3. In both cases, a difference is observed in the wildtype background (p = 7.5x10-5 
for SOK2 and 5.0x10-3 for MOT3), but not the RM AA112∆ background (p = 0.28 for SOK2 and 
0.67 for MOT3), consistent with the TF regulation being entirely abolished by the deletion. (D) 
Chromatin immunoprecipitation data showing the difference in binding for Sok2 and Mot3 to the 
ERG28 promoter in wildtype RM / RM AA112∆. In both cases a significant decrease in binding 
is observed in RM AA112∆.  
 
Figure 4. Fitness effect of the causal mutation. (A) In rich synthetic defined (SD) media, the RM 
AA112∆ strain and RM T229C strains show no significant difference from RM. (B) In the 
presence of the antifungal drug amphotericin B, the RM AA112∆ strain shows a growth rate 
advantage over RM, whereas the RM T229C strain shows no difference from RM. Bars represent 
the mean log2 ratios of maximum log-phase growth rates from 48 replicate cultures, +/- 1 S.E.  
 
Figure S1. Phylogeny of S. cerevisiae (adapted from [37]), with strains containing the AA112∆ 
allele marked with an asterisk. Branch lengths are not to scale. “SGD” and “S288c” are nearly 
identical to BY, so are not counted among the 12 non-BY strains with AA112∆. 
 
Table S1. All PCR primers used in this work. 
 
Table S2. All yeast strains used in this work. 
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